Background Immunotherapy emerged as a promising treatment option for multiple myeloma (MM) patients. However. therapeutic efficacy can be hampered by the presence of an immunosuppressive bone marrow microenvironment including myeloid cells. S100A9 was previously identified as a key regulator of myeloid cell accumulation and suppressive activity. https://parisnaturalfoodes.shop/product-category/soy-free-vegenaise/